Editas Medicine Inc. (EDIT)
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EDIT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $253.12M
- EPS (TTM)
- -$0.54
- Dividend yield
- None
- 52-week range
- 1.63 – 3.94
- Day range
- 1.63 – 1.78
- Volume / Avg
- 2.68M / 2.63M
- Beta
- —
- Shares outstanding
- 154.34M
52-week range
EDIT stock today
Shares of Editas Medicine (EDIT) finished lower on Nov 20 at $1.64, a drop of 4.09% or $0.07 per share, versus the S&P 500's 3.70% decline. At this level, EDIT sits near the bottom of its 52-week range of $1.63 to $3.94: 58.4% below the high, set on May 27, 2026 and 0.6% above the low. EDIT is down 20.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 32.2%.
Editas Medicine has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Editas Medicine
Company profileEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Gilmore O'Neill M.D.
- Headquarters
- Cambridge, MA
- Employees
- 87
- IPO year
- 2016
- Website
- editasmedicine.com
Financial highlights
Full financialsIn fiscal 2025, Editas Medicine generated $40.5 million in revenue, up 25.4% from fiscal 2024. Editas Medicine reported a net loss of $160.1 million, compared with a loss of $237.1 million a year earlier. Operating margin was -394.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $40.52M | $32.31M | $78.12M | $19.71M | $25.54M |
| Growth | +25.39% | -58.64% | +296.32% | -22.83% | -71.85% |
| Net income | $-160.06M | $-237.09M | $-153.22M | $-220.43M | $-192.50M |
| EPS (diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$6.10+271.95%
- Strong buy 0
- Buy 9
- Hold 2
- Sell 0
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.15 vs $-0.21
- Surprise
- +28.57%
EDIT news
All EDIT news- Editas Medicine, Inc. Reports Third Quarter 2026 Net Loss of $23.4 millionNasdaq
- EDITAS MEDICINE, INC. Q3 Loss DecreasesNasdaq
- Editas Medicine Announces Third Quarter 2026 Results and Business UpdatesGlobeNewswire
- EDIT Set to Begin First-in-Human Study in HypercholesterolemiaNasdaqEDIT, ALNY, AMRN, ALDX
- Wells Fargo Upgrades Editas Medicine to Overweight from Equal-WeightNasdaq
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with HyperlipidemiaGlobeNewswire
Editas Medicine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs EDIT |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs EDIT |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs EDIT |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs EDIT |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs EDIT |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs EDIT |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs EDIT |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs EDIT |
Indexes, lists and sector
Editas Medicine stock FAQ
What is Editas Medicine's stock price today?
EDIT last traded at $1.64 as of Nov 20, 4:00 PM EST, down 4.09% on the day. Prices are delayed at least 15 minutes.
Who is Editas Medicine's CEO?
Dr. Gilmore O'Neill M.D. is the chief executive officer of Editas Medicine Inc., which has about 87 employees.
What is the EDIT 52-week high?
The 52-week high for EDIT is $3.94 and the 52-week low is $1.63. The stock is currently 58.4% below its high.